Japan, Nov. 7 -- The Japan Foundation of Cancer Research (JFCR) and NEC Corporation have confirmed research results supporting the development of a novel personalized neoantigen cancer vaccine using whole-genome data. Analysis utilizing NEC's proprietary AI technology from breast cancer and soft tissue sarcoma has successfully enabled the prediction of numerous cancer-specific antigens (cryptic antigens) originating from dark genomes-regions of the genome whose function and role remain largely unexplored-in addition to conventional neoantigens. Developing vaccines using these antigens could potentially offer new treatment options for cancers that have been difficult to treat until now.Both organizations will present these findings at the an...